Home › NCT07245420

Evaluation Of Cardiovascular Health Outcomes Among Survivors 2

Evaluation Of Cardiovascular Health Outcomes Among Survivors 2 (ECHOS2)

Who can join

Ages 26 and older · All sexes

Inclusion Criteria:

* Childhood Cancer Survivor Study (CCSS) Participants
* Age ≥26 years
* Treated with cumulative doxorubicin equivalent anthracycline doses ≥100 mg/m2 with any/no radiation, or ≥15 Gy chest radiation with any/no anthracyclines
* No history of cardiomyopathy
* Has not had an echocardiogram in the previous 5 years
* Has a history of successful completion of CCSS surveys
* English-Speaking
* Has not been enrolled in ECHOS-1 (pilot)

Exclusion Criteria:

• Currently participating in a long-term follow-up program that provides risk-based screening

About the study

Childhood cancer survivors who received certain treatments are at a higher risk of developing heart problems in the future. This study is looking at ways to educate childhood cancer survivors about that risk and encourage them to receive a recommended heart screening test.

What is being tested

• Survivorship Care Plan + Educational Materials (delivered via CIAS platform) (behavioral)
• Healthy Hearts eHealth Program (behavioral)

Sponsor: St. Jude Children's Research Hospital · Participants: 350 · Started: 2026-09

Contact the study team

• Matthew Ehrhardt, MD, MS, MPI · Phone: 888-226-4343

Official record on ClinicalTrials.gov — NCT07245420

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.